Crohn's Disease Clinical Trial
Official title:
A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Verified date | October 2022 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD. Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide. In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 14, 2022 |
Est. primary completion date | October 14, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Confirmed diagnosis of UC or CD for at least 3 months prior to Day -1 (baseline). Appropriate documentation of biopsy results consistent with the diagnosis of CD or UC, in the assessment of the gastroenterologist, must be available. - Moderately to severely active CD or UC. - Must have demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates, oral locally acting steroids, systemic steroids, immunomodulators, and/or approved biologic therapies. - Participant must agree to not use any known inhibitors or inducers of cytochrome P450 within 1 month or 5 half-lives, whichever is greater before each administration of the cocktail probe and until the last pharmacokinetic sample is collected, 7 days after the intake of each probe cocktail. Exclusion Criteria: - History of any clinically significant sensitivity or allergy to any medication or food. - History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption (e.g., celiac disease, gastroparesis, cholecystectomy, vagotomy). - Positive for COVID-19 infection signs and symptoms. |
Country | Name | City | State |
---|---|---|---|
Germany | Charite Research Organisation GmbH /ID# 218646 | Berlin | |
Israel | The Chaim Sheba Medical Center /ID# 223959 | Ramat Gan | Tel-Aviv |
United States | Southern California Res. Ctr. /ID# 216257 | Coronado | California |
United States | University Clinical Research /ID# 216823 | DeLand | Florida |
United States | Atlantic Medical Research Group /ID# 227465 | Margate | Florida |
United States | Clinical Trials of Texas, Inc /ID# 216277 | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
United States, Germany, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Observed Plasma Concentration (Cmax) of Midazolam | Maximum observed plasma concentration (Cmax) of Midazolam | Up to 71 Days | |
Primary | Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam | Time to maximum plasma concentration (Tmax) of Midazolam | Up to 71 Days | |
Primary | Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration | Up to 71 Days | |
Primary | AUC From Time 0 to Infinity (AUCinf) of Midazolam | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity | Up to 71 Days | |
Primary | Terminal Phase Elimination Rate Constant (ß) of Midazolam | Terminal phase elimination rate constant (ß) for Midazolam | Up to 71 Days | |
Primary | Terminal Phase Elimination Half-Life (t1/2) of Midazolam | Terminal phase elimination half-life (t1/2) of Midazolam | Up to 71 Days | |
Primary | Maximum Observed Plasma Concentration (Cmax) of Caffeine | Maximum observed plasma concentration (Cmax) of Caffeine | Up to 71 Days | |
Primary | Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine | Time to maximum plasma concentration (Tmax) of Caffeine | Up to 71 Days | |
Primary | Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration | Up to 71 Days | |
Primary | AUC From Time 0 to Infinity (AUCinf) of Caffeine | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity | Up to 71 Days | |
Primary | Terminal Phase Elimination Rate Constant (ß) of Caffeine | Terminal phase elimination rate constant (ß) for Caffeine | Up to 71 Days | |
Primary | Terminal Phase Elimination Half-Life (t1/2) of Caffeine | Terminal phase elimination half-life (t1/2) of Caffeine | Up to 71 Days | |
Primary | Maximum Observed Plasma Concentration (Cmax) of Warfarin | Maximum observed plasma concentration (Cmax) of Warfarin | Up to 71 Days | |
Primary | Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin | Time to maximum plasma concentration (Tmax) of Warfarin | Up to 71 Days | |
Primary | Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration | Up to 71 Days | |
Primary | AUC From Time 0 to Infinity (AUCinf) of Warfarin | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity | Up to 71 Days | |
Primary | Terminal Phase Elimination Rate Constant (ß) of Warfarin | Terminal phase elimination rate constant (ß) for Warfarin | Up to 71 Days | |
Primary | Terminal Phase Elimination Half-Life (t1/2) of Warfarin | Terminal phase elimination half-life (t1/2) of Warfarin | Up to 71 Days | |
Primary | Maximum Observed Plasma Concentration (Cmax) of Omeprazole | Maximum observed plasma concentration (Cmax) of Omeprazole | Up to 71 Days | |
Primary | Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole | Time to maximum plasma concentration (Tmax) of Omeprazole | Up to 71 Days | |
Primary | Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration | Up to 71 Days | |
Primary | AUC From Time 0 to Infinity (AUCinf) of Omeprazole | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity | Up to 71 Days | |
Primary | Terminal Phase Elimination Rate Constant (ß) of Omeprazole | Terminal phase elimination rate constant (ß) for Omeprazole | Up to 71 Days | |
Primary | Terminal Phase Elimination Half-Life (t1/2) of Omeprazole | Terminal phase elimination half-life (t1/2) of Omeprazole | Up to 71 Days | |
Primary | Maximum Observed Plasma Concentration (Cmax) of Metoprolol | Maximum observed plasma concentration (Cmax) of Metoprolol | Up to 71 Days | |
Primary | Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol | Time to maximum plasma concentration (Tmax) of Metoprolol | Up to 71 Days | |
Primary | Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration | Up to 71 Days | |
Primary | AUC From Time 0 to Infinity (AUCinf) of Metoprolol | Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity | Up to 71 Days | |
Primary | Terminal Phase Elimination Rate Constant (ß) of Metoprolol | Terminal phase elimination rate constant (ß) for Metoprolol | Up to 71 Days | |
Primary | Terminal Phase Elimination Half-Life (t1/2) of Metoprolol | Terminal phase elimination half-life (t1/2) of Metoprolol | Up to 71 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |